STOCK TITAN

Spruce Biosciences, Inc. - $SPRB STOCK NEWS

Welcome to our dedicated page for Spruce Biosciences news (Ticker: $SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spruce Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spruce Biosciences's position in the market.

Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported financial results for Q3 2023, highlighted by the completion of enrollment in the CAHptain-205 and CAHmelia-203 studies for rare endocrine disorders. The company also provided updates on upcoming milestones and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in the Jefferies London Healthcare Conference on November 14-16, 2023. Archived webcasts from investor conferences are available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
Rhea-AI Summary
Spruce Biosciences has announced the completion of target enrollment in the CAHmelia-203 clinical trial for the treatment of adult classic congenital adrenal hyperplasia (CAH). The company has enrolled 72 patients and closed screening in the trial. Final enrollment is expected to exceed the original target due to substantial patient interest. The topline results from this study, along with the results from all cohorts in the CAHptain clinical trial, are anticipated in the first quarter of 2024. Spruce Biosciences also provided updated anticipated milestones for other ongoing trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.97%
Tags
none
Rhea-AI Summary
Spruce Biosciences to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported interim data from the Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) and provided corporate updates. The study assessed the ability of tildacerfont to reduce DHEAS in women with PCOS. The interim results support target engagement and suggest that DHEAS may be reduced with tildacerfont treatment. Enrollment in the CAHmelia program in adult classic CAH surpassed 75%, and screening for Cohort 3 in the CAHptain Study for pediatric classic CAH is underway. The company also reported financial results for the second quarter ended June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
none
Rhea-AI Summary
Spruce Biosciences appoints Percival Barretto-Ko to its Board of Directors and announces the departure of Dina Chaya. Barretto-Ko brings over 20 years of commercial and biopharmaceutical expertise. The company is focused on developing novel therapies for rare endocrine disorders. Barretto-Ko's global experience will be valuable as Spruce prepares for the potential commercialization of tildacerfont.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.08%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.08%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
Spruce Biosciences, Inc.

Nasdaq:SPRB

SPRB Rankings

SPRB Stock Data

32.92M
13.54M
7.75%
71.24%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About SPRB

spruce biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.